Dm in-depth
Overview of Diabetes Mellitus and Epidemiology
Etymology and Historical Context:
The term diabetes derives from the Greek word for "fountain" and the Latin word for "honey."
It describes the production of large volumes of glucose-rich urine in untreated patients. Historically, diagnosis was made by the sweet smell and taste of urine.
Pathophysiology Overview:
Primary disorder of carbohydrate metabolism, though insulin deficiency or resistance also severely disrupts protein and lipid metabolism.
Principal sign: Sustained hyperglycemia resulting from impaired cellular glucose uptake and increased hepatic glucose production.
Acute symptoms: Polyuria, polydipsia, ketonuria, and rapid weight loss.
Long-term vascular and neurological complications: Heart disease, renal failure, blindness, neuropathy, impotence, and stroke.
Epidemiology and Prevalence (CDC 2022 Report):
Diabetes is the most common endocrine disorder and the seventh leading cause of death by disease in the United States.
Approximately Americans have diabetes, and nearly one-fourth () are undiagnosed.
An estimated US adults (ages and older) have prediabetes.
Etiology and Classification of Diabetes
Type 1 Diabetes (T1D):
Prevalence & Onset: Accounts for approximately of all diabetes cases. Usually develops during childhood or adolescence with an abrupt onset of symptoms, though it can manifest in adulthood.
Primary Defect: Autoimmune destruction of pancreatic cells in the Islets of Langerhans, which synthesize and release insulin. Insulin levels are reduced early in the disease and fall to zero over time.
Etiology: Triggered by an autoimmune process influenced by genetic, environmental, and infectious factors.
Clinical Profile: High risk for ketoacidosis; patients are typically thin/undernourished at diagnosis; family history is frequently negative.
Blood Glucose Stability: Fluctuates widely in response to infection, exercise, caloric intake, and insulin dose variations.
Management: Mandatory daily insulin replacement coordinated with strict dietary control.
Type 2 Diabetes (T2D):
Prevalence & Onset: Accounts for of all diagnosed cases. Typically begins in middle age and progresses gradually, though childhood onset has increased significantly.
Primary Defect: Combination of target tissue insulin resistance and impaired insulin secretion. Pancreatic cells retain the capacity to synthesize insulin, but release is delayed and peak output is subnormal.
Mechanism of Insulin Resistance: Target tissues (liver, skeletal muscle, adipose tissue) exhibit reduced insulin binding to receptors, reduced receptor numbers, and reduced receptor responsiveness. Over time, hyperglycemia causes -cell exhaustion, leading to declining insulin synthesis.
Etiology: Strong familial association; implicated genes include insulin receptor substrate-2 (), which mediates intracellular responses to insulin.
Clinical Profile: Low risk for ketoacidosis; patients are frequently obese at diagnosis; family history is frequently positive; blood glucose levels are generally more stable than in T1D.
Management: Oral antidiabetic agents, non-insulin injectables, and/or insulin, always combined with a reduced-calorie diet and structured exercise.
Comparative Summary of Diabetes Types (Table 48-1):
Age of Onset: T1D = usually childhood/adolescence; T2D = usually older than .
Speed of Onset: T1D = abrupt; T2D = gradual.
Family History: T1D = frequently negative; T2D = frequently positive.
Primary Defect: T1D = loss of pancreatic cells; T2D = insulin resistance and inappropriate insulin secretion.
Insulin Levels: T1D = reduced early, absent later; T2D = low, normal, or high.
Ketoacidosis: T1D = common; T2D = uncommon.
Gestational Diabetes & Diabetes in Pregnancy:
Definition: Diabetes appearing during pregnancy that subsides rapidly after delivery.
Pathophysiologic Factors in Pregnancy:
Placental hormones antagonize insulin actions.
Cortisol production increases threefold () during pregnancy, promoting hyperglycemia.
Maternal hyperglycemia causes glucose to pass freely across the placenta, stimulating fetal hyperinsulinism, which leads to fetal macrosomia and adverse birth outcomes.
Management: Requires diligent glucose control. Insulin is the preferred agent; metformin is used in select cases.
Diagnostic Criteria and Prediabetes
Criteria for the Diagnosis of Diabetes (Table 48-2):
Fasting Plasma Glucose (FPG): (fasting defined as no caloric intake for at least ).
Random Plasma Glucose: plus classic symptoms of diabetes (polyuria, polydipsia, unexplained weight loss).
Oral Glucose Tolerance Test (OGTT): 2-hour plasma glucose following ingestion of anhydrous glucose dissolved in water.
Hemoglobin A1c: or higher.
Prediabetes Guidelines:
Diagnostic Parameters: Impaired Fasting Glucose () OR Impaired Glucose Tolerance (2-hour ).
Associated Risks: Increased risk for developing T2D and cardiovascular disease (CVD), but NOT microvascular complications (retinopathy, nephropathy, neuropathy).
Interventions: Moderate exercise plus weight loss ( of body weight) reduces T2D progression risk by overall (and in adults age ).
Management Overview and Glycemic Targets
Comprehensive Management Goals:
Achieve safe glycemic control while minimizing hypoglycemia.
Manage comorbidities: Hypertension (2023 ADA target using ACE inhibitors like lisinopril or ARBs like losartan) and Dyslipidemia (using HMG-CoA reductase inhibitors/statins to reduce CV events).
General Glycemic Treatment Targets for Nonpregnant Adults (Table 48-3):
Hemoglobin A1c: (Individualized target for patients with severe hypoglycemia history, limited life expectancy, or advanced complications).
Premeal (Preprandial) Plasma Glucose: .
Peak Postprandial Plasma Glucose (1--2 hours post-meal): .
Hemoglobin A1c and Estimated Average Glucose (eAG) Conversion (Table 48-4):
Conversion Formula:
Stepwise Management Approach in Type 2 Diabetes:
Step 1: Lifestyle modifications plus Metformin monotherapy at diagnosis.
Step 2: Lifestyle modifications + Metformin + a second high-efficacy drug (e.g., GLP-1 RA or SGLT-2 inhibitor). Consider basal insulin if target is unmet.
Step 3: Progress to a three-drug combination based on patient risk factors, social determinants, cost, and preferences.
Initial Combination Therapy Exceptions:
If at diagnosis: Consider dual therapy immediately (Step 2).
If , , or patient is markedly symptomatic: Consider immediate combination injectable therapy.
Insulin Physiology, Actions, and Complications
Endogenous Physiology:
Synthesized in pancreatic cells in the Islets of Langerhans.
Primary release stimulus: Elevation in blood glucose (eating a carbohydrate-rich meal).
Additional release triggers: Amino acids, fatty acids, ketone bodies, and incretins (GLP-1).
Autonomic Regulation: -adrenergic receptor activation promotes insulin secretion; -adrenergic receptor activation suppresses secretion.
Metabolic Actions of Insulin (Table 48-5):
Anabolic Mode:
Carbohydrates: Stimulates glucose uptake in muscle/adipose tissue; stimulates glucose oxidation in muscle; stimulates glycogen synthesis and storage in muscle/liver. Inhibits glycogenolysis and gluconeogenesis.
Amino Acids & Proteins: Stimulates amino acid uptake and protein synthesis in muscle; inhibits amino acid release.
Lipids: Stimulates triglyceride synthesis in adipose tissue; inhibits free fatty acid (FFA) and glycerol release; inhibits FFA oxidation to ketoacids in the liver.
Catabolic Mode (Insulin Deficiency):
Glycogen is broken down to glucose (glycogenolysis); gluconeogenesis is accelerated using amino acids and glycerol; proteins are degraded; fats are converted to FFAs and glycerol.
Complications of Insulin Therapy:
Hypoglycemia (Blood Glucose ):
Causes: Insulin overdose, decreased food intake, vomiting/diarrhea, excessive alcohol consumption, intense physical activity.
Sympathetic Symptoms (Rapid Decline): Tachycardia, palpitations, sweating, nervousness.
CNS Symptoms (Gradual Decline): Headache, confusion, drowsiness, fatigue; progresses to convulsions, coma, and death.
Treatment: Conscious: fast-acting oral carbohydrates (glucose tablets, orange juice, sugar cubes, honey, non-diet soda). Unconscious/Gag Reflex Suppressed: IV dextrose () or parenteral glucagon.
Hypoglycemia Unawareness: Lack of sympathetic warning signs due to recurrent hypoglycemia; managed by temporarily loosening glycemic targets for several weeks.
Hypokalemia: Insulin stimulates -ATPase, pumping potassium into cells. Excessive insulin causes severe hypokalemia, resulting in cardiac dysrhythmias and reduced contractility.
Lipohypertrophy: Accumulation of subcutaneous fat at injection sites due to localized insulin-stimulated lipid synthesis. Prevented by rotating injection sites.
Drug Interactions with Insulin:
Hypoglycemic Agents: Sulfonylureas, glinides, and alcohol intensify insulin-induced hypoglycemia.
Hyperglycemic Agents: Thiazide diuretics, glucocorticoids, sympathomimetics, and antipsychotics raise blood glucose and counteract insulin.
-Adrenergic Blockers: Mask sympathetic warning signs of hypoglycemia (tachycardia, palpitations) and impair glycogenolysis.
Insulin Preparations and Pharmacokinetics
Short Duration: Rapid Acting:
Insulin Lispro (Humalog): Onset = ; Peak = ; Duration = . Strengths: U-100, U-200. SubQ injection within before or immediately after meals; SubQ continuous infusion pump; IV (rare). Rx.
Insulin Aspart (NovoLog): Onset = ; Peak = ; Duration = . Strength: U-100. SubQ injection before meals; SubQ pump; IV (rare). Rx.
Insulin Glulisine (Apidra): Onset = ; Peak = ; Duration = . Strength: U-100. SubQ injection within before or after meals; SubQ pump; IV (rare). Rx.
Inhaled Human Insulin (Afrezza): Mealtime rapid-acting dry powder inhaler. Cartridge strengths: , , and . Rx.
Short Duration: Short Acting:
Regular Insulin (Humulin R, Novolin R):
Onset = ; Peak = ; Duration = . SubQ injection before meals, SubQ pump, IV infusion, IM (rare).
Strengths: U-100 (OTC) and U-500 (, Rx). U-500 is reserved for extreme insulin resistance (). NEVER administer U-500 IV; always use dedicated U-500 syringes.
Intermediate Duration:
Neutral Protamine Hagedorn (NPH) Insulin Suspension (Humulin N, Novolin N):
Conjugated with protamine (foreign protein; risk of allergic reactions).
Onset = ; Peak = ; Duration = . SubQ injection twice daily. Cloudy suspension (agitate gently prior to drawing). Only intermediate/long-acting insulin suitable for mixing with short-acting insulins. OTC.
Long Duration:
Insulin Glargine U-100 (Lantus, Basaglar, Semglee): Onset = ; Peak = None (peakless steady state); Duration = . SubQ once or twice daily at the same time every day. Forms SubQ microprecipitates that slowly dissolve. Rx.
Insulin Detemir (Levemir): Onset = ; Peak = ; Duration = dose-dependent (; ). Being discontinued after December 2024. Rx.
Ultra-Long Duration:
Insulin Glargine U-300 (Toujeo): Onset = ; Peak = None; Duration = . SubQ once daily. Rx.
Insulin Degludec (Tresiba): Onset = ; Peak = None; Duration = . Strengths: U-100, U-200. SubQ once daily. Rx.
Premixed Insulin Combinations (Table 48-8):
NPH / Regular (Humulin 70/30, Novolin 70/30): OTC.
NPH / Regular (Humulin 50/50): OTC.
Insulin aspart protamine / Insulin aspart (NovoLog Mix 70/30): Rx.
Insulin lispro protamine / Insulin lispro (Humalog Mix 75/25): Rx.
Insulin lispro protamine / Insulin lispro (Humalog Mix 50/50): Rx.
Rules for Mixing Insulins:
Mix only compatible insulins. Only NPH is approved for mixing with short-acting insulins (regular, lispro, aspart, glulisine).
Always draw the short-acting (clear) insulin into the syringe FIRST to prevent contaminating the short-acting vial with NPH (cloudy).
Dosing Regimens:
Total daily dosage: . T1D initial = ; T2D initial = .
Regimens: Twice-daily premixed vs. Intensive basal-bolus strategy (basal insulin once daily + rapid-acting insulin before each meal).
Insulin requirements increase with: Infection, stress, obesity, adolescent growth spurt, pregnancy (2nd/3rd trimesters).
Insulin requirements decrease with: Exercise, 1st trimester of pregnancy.
Oral Antidiabetic Medications
1. Biguanides: Metformin (Glucophage, Glucophage XR, Fortamet, Glumetza, Riomet):
Mechanism of Action: Inhibits hepatic glucose production; reduces intestinal glucose absorption; sensitizes insulin receptors in target tissues (skeletal muscle and fat) to increase glucose uptake. Does NOT stimulate pancreatic insulin release (no risk of hypoglycemia when used alone).
Pharmacokinetics: Slowly absorbed in small intestine. NOT metabolized by the liver; excreted UNCHANGED by the kidneys. Half-life = . Accumulates in renal impairment.
Therapeutic Uses: First-line therapy for T2D; prevention of T2D in high-risk patients; gestational diabetes; Polycystic Ovary Syndrome (PCOS - off-label, improves insulin sensitivity, lowers androgen levels, restores ovulation).
Adverse Effects: GI disturbances (decreased appetite, nausea, diarrhea; causes discontinuation in ; minimize by titrating slowly and taking with meals); Decreased Vitamin and folic acid absorption; Weight neutral or modest weight loss.
BLACK BOX WARNING / Lactic Acidosis: Severe, potentially fatal ( mortality) metabolic acidosis caused by metformin accumulation. Metformin inhibits mitochondrial oxidation of lactic acid. Extremely rare () with normal renal function. CONTRAINDICATED in renal impairment, liver disease, severe infection, alcoholism, shock/hypoxia. Early signs: hyperventilation, myalgia, malaise, unusual somnolence. Treatment: drug withdrawal, hemodialysis.
Drug Interactions: Alcohol (potentiates lactic acidosis); Cimetidine (increases lactic acidosis risk); Iodinated Radiocontrast Media (causes acute renal failure; withhold metformin prior to contrast procedures, resume post-procedure if renal function is normal).
Dosing: Immediate Release (IR) starting daily or BID (max ); Extended Release (ER) starting daily (max ).
2. Second-Generation Sulfonylureas: Glipizide (Glucotrol), Glyburide (DiaBeta, Glynase), Glimepiride (Amaryl):
Mechanism of Action: Stimulates insulin release from pancreatic cells by blocking ATP-sensitive channels membrane depolarization influx insulin exocytosis.
Adverse Effects: Hypoglycemia (doses lower blood glucose regardless of baseline levels; severe risk in renal/hepatic impairment), Weight gain.
Drug Interactions: Alcohol (disulfiram-like reaction: flushing, palpitations, nausea; potentiates hypoglycemia); NSAIDs, sulfonamide antibiotics, cimetidine (intensify hypoglycemia); -blockers (suppress insulin release, mask hypoglycemic tachycardia).
Dosing: Glipizide IR (max ); Glipizide ER (max ); Glyburide nonmicronized (max ), micronized (max ); Glimepiride (max ). Hold if patient is NPO.
3. Meglitinides (Glinides): Repaglinide (Prandin), Nateglinide (Starlix):
Mechanism of Action: Same as sulfonylureas (blocks ATP-sensitive channels on cells).
Pharmacokinetics: Rapid onset, short duration. Taken within before meals. Nateglinide duration = (renally excreted); Repaglinide duration = ( renally excreted, safer in renal impairment).
Adverse Effects: Hypoglycemia, Weight gain. Skip dose if meal is skipped.
Drug Interaction: Gemfibrozil + Repaglinide: Gemfibrozil inhibits CYP2C8, dramatically increasing repaglinide levels and causing severe hypoglycemia (combination contraindicated).
4. Thiazolidinediones (TZDs / Glitazones): Pioglitazone (Actos):
Mechanism of Action: Activates PPAR- (peroxisome proliferator-activated receptor gamma) in cell nucleus turns on insulin-responsive genes decreases insulin resistance, increases glucose uptake in muscle/fat, decreases hepatic glucose output. Requires presence of insulin.
BLACK BOX WARNING / Heart Failure: Renal fluid retention. Contraindicated in NYHA Class III and Class IV Heart Failure.
Adverse Effects: Upper respiratory tract infection, headache, myalgia, sinusitis; Bladder Cancer risk (long-term high dose; avoid in active/history of bladder cancer); Fractures in cisgender women (foot, hand, upper arm); Hepatotoxicity (monitor ALT at baseline and q3-6mo; stop if ALT or jaundice); Risk of ovulation/unintended pregnancy in anovulatory premenopausal women.
Drug Interactions: Insulin (increases fluid retention/HF risk); CYP2C8 inhibitors (gemfibrozil) increase levels; CYP2C8 inducers (rifampin) decrease levels.
5. -Glucosidase Inhibitors: Acarbose (Precose), Miglitol (Glyset):
Mechanism of Action: Reversibly inhibits -glucosidase at the intestinal brush border delays digestion and absorption of complex carbohydrates and oligosaccharides reduces postprandial blood glucose spike.
Adverse Effects: GI distress (flatulence, abdominal cramps, distension, borborygmi, diarrhea due to bacterial fermentation of unabsorbed carbs in colon), Decreased iron absorption (anemia).
Hypoglycemia Treatment Rule: Does not cause hypoglycemia alone. If combined with insulin/sulfonylurea and hypoglycemia occurs, MUST treat with pure glucose (dextrose), NOT sucrose (table sugar), because acarbose inhibits sucrose hydrolysis.
Hepatotoxicity: Long-term high-dose acarbose can elevate liver transaminases (monitor q3mo for 1st year).
6. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (Gliptins): Sitagliptin (Januvia), Saxagliptin (Onglyza), Linagliptin (Tradjenta), Alogliptin (Nesina):
Mechanism of Action: Inhibits DPP-4 enzyme prevents degradation of incretin hormones (GLP-1, GIP) increases glucose-dependent insulin secretion, suppresses postprandial glucagon release, decreases hepatic glucose output.
Adverse Effects: Generally well tolerated (nasopharyngitis, headache, URI). Low risk of hypoglycemia alone. Rare: Acute pancreatitis (severe, persistent abdominal pain; stop drug immediately), severe hypersensitivity (anaphylaxis, angioedema, Stevens-Johnson syndrome), heart failure risk (saxagliptin, alogliptin).
7. Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors: Canagliflozin (Invokana), Dapagliflozin (Farxiga), Empagliflozin (Jardiance), Ertugliflozin (Steglatro), Bexagliflozin (Brenzavvy):
Mechanism of Action: Inhibits SGLT-2 in proximal renal tubules blocks reabsorption of filtered glucose increases urinary glucose excretion (glucosuria) lowers blood glucose and promotes weight loss via caloric loss in urine.
Adverse Effects: Female genital mycotic infections, UTIs (urosepsis, pyelonephritis), postural hypotension/dizziness (due to osmotic diuresis; exacerbated by diuretics), euglycemic DKA (rare in T2D), Fournier's gangrene (necrotizing fasciitis of perineum), lower limb amputation risk (canagliflozin).
Drug Interactions: UGT inducers (rifampin, phenytoin, phenobarbital) decrease canagliflozin levels; diuretics increase dehydration/hypotension.
8. Other Oral Antidiabetic Agents:
Colesevelam (Welchol): Bile acid sequestrant; lowers cholesterol and lowers blood glucose in T2D.
Bromocriptine (Cycloset): Dopamine agonist; acts in CNS to adjust metabolic control; reduces A1c by .
Non-Insulin Injectable Antidiabetic Medications
1. GLP-1 Receptor Agonists (Incretin Mimetics):
Agents & Dosing:
Exenatide IR (Byetta): SubQ injection BID within before morning and evening meals ().
Exenatide ER (Bydureon): SubQ injection once weekly ().
Liraglutide (Victoza): SubQ once daily ( titrating to ). Saxenda brand used for obesity ().
Dulaglutide (Trulicity): SubQ once weekly ().
Semaglutide (Ozempic): SubQ once weekly (). Rybelsus is oral daily formulation (). Wegovy brand used for obesity.
Mechanism of Action: Synthetic analogs that activate GLP-1 receptors slow gastric emptying, stimulate glucose-dependent insulin release, suppress postprandial glucagon release, reduce appetite.
Adverse Effects: GI distress (nausea, vomiting, diarrhea), hypoglycemia (when combined with sulfonylureas), acute pancreatitis (severe abdominal pain; discontinue), renal impairment secondary to dehydration/N/V/D.
BLACK BOX WARNING (Liraglutide, Dulaglutide, Semaglutide, Exenatide ER): Risk of thyroid C-cell tumors / Medullary Thyroid Carcinoma (MTC). Contraindicated in personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
2. Dual GIP and GLP-1 Receptor Agonist:
Tirzepatide (Mounjaro for T2D; Zepbound for obesity):
Mechanism of Action: Dual agonist at both GIP and GLP-1 receptors enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, markedly increases satiety profound weight loss ().
Dosing: SubQ once weekly ( starting, titrate by q4wk up to max ).
Adverse Effects: GI effects (N/V/D, constipation, abdominal pain), pancreatitis, acute kidney injury.
Interactions: May decrease effectiveness of oral contraceptives (advise alternative birth control method).
3. Amylin Mimetics:
Pramlintide (Symlin):
Mechanism of Action: Synthetic analog of amylin (co-secreted with insulin by cells) delays gastric emptying, suppresses glucagon secretion, increases satiety.
Indication: Adjunct to mealtime insulin in T1D and T2D.
BLACK BOX WARNING / Hypoglycemia: Severe, insulin-induced hypoglycemia when combined with mealtime insulin, especially in T1D (occurs within of dosing). Reduce mealtime insulin dose by initially upon starting pramlintide. Contraindicated in hypoglycemia unawareness, poor adherence, or recurrent hypoglycemia.
Interactions: Delays oral drug absorption due to slowed gastric emptying (take oral meds before or after pramlintide). Avoid with drugs that slow GI motility (antimuscarinics, opioids) or slow nutrient absorption (acarbose).
4. Combination Injectable Products:
Soliqua 100/33: Fixed-dose combination of Insulin glargine + Lixisenatide (SubQ once daily).
Xultophy 100/3.6: Fixed-dose combination of Insulin degludec + Liraglutide (SubQ once daily).
Acute Complications: DKA, HHS, and Severe Hypoglycemia
Comparison of DKA and HHS (Table 48-21):
Diabetic Ketoacidosis (DKA):
Patient Population: Mainly Type 1 Diabetes.
Onset: Rapid (hours to days).
Blood Glucose Level: .
Arterial Blood pH: .
Plasma Osmolality: .
Ketones: Large increase in blood and urine ketones.
Odor: Urine smells like rotten apples; breath smells sweet/fruity or like acetone (nail polish remover).
Pathogenesis: Severe insulin deficiency uncontrolled lipolysis FFA accumulation hepatic oxidation of FFAs into ketoacids (-hydroxybutyric acid, acetoacetic acid) metabolic acidosis + osmotic diuresis/dehydration hemoconcentration, shock, coma, death.
Treatment: IV fluids and electrolytes (normalize and balance), followed by IV regular insulin infusion. Reduce blood glucose slowly at a rate of .
Hyperosmolar Hyperglycemic State (HHS):
Patient Population: Mainly Type 2 Diabetes.
Onset: Gradual (evolves over weeks to months).
Blood Glucose Level: .
Arterial Blood pH: .
Plasma Osmolality: .
Ketones: Little or no change (nonketotic).
Odor: Normal urine and breath odor.
Pathogenesis: Insulin deficiency allows extreme hyperglycemia and severe osmotic diuresis profound dehydration, hemoconcentration, increased hematocrit, sluggish blood flow seizures, coma, death.
Treatment: IV fluids, electrolytes, and IV regular insulin infusion.
Glucagon for Severe Hypoglycemia:
Source & Physiology: Polypeptide hormone produced by cells in pancreatic Islets of Langerhans. Acts opposite to insulin by promoting glycogenolysis, inhibiting glycogen synthesis, and stimulating gluconeogenesis.
Indication: Treatment of severe hypoglycemia in ambulatory/home settings when IV glucose is unavailable.
Dosing & Administration: SubQ, IM, or IV injection ( reconstituted powder); Intranasal formulation (Baqsimi); Ready-to-inject pen (Gvoke).
Clinical Considerations: Restores consciousness within . Once conscious, administer oral carbohydrates immediately to prevent recurrent hypoglycemia and replenish liver glycogen stores. Ineffective in starved patients (depleted hepatic glycogen).